AI Terminal
ABIONYX Pharma
Report Publication Announcement • Mar 7, 2024
1062_iss_2024-03-07_8bea2e08-2c32-4dbb-9742-e30ec6b1fe09.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
ABIONYX Pharma announces its financial calendar for the year 2024
Toulouse, FRANCE, Lakeland, UNITED-STATES, March 7th, 2024, 7:00 pm CET – ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant apoA-I, today announces its financial calendar for 2024.
| Events | Dates* |
|---|---|
| 2023 Full-Year Results | Monday, March 11, 2024 |
| Cash position and activity update for Q1 2024 | Thursday, May 16, 2024 |
| Cash position and activity update for Q2 2024 | Thursday, August 22, 2024 |
| 2024 Half-Year Results | Thursday, September 26, 2024 |
| Cash position and activity update for Q3 2024 | Thursday, November 14, 2024 |
* indicative dates subject to change
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicinesin diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I -based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in sepsis and critical care.
Contacts:
NewCap Investor relations Nicolas Fossiez Louis-Victor Delouvrier [email protected] +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé [email protected] +33 (0)1 44 71 00 15